Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

 
• By Derrick Gingery
  
FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee votes 6-6 on whether the risk-benefit profile for Sutent's indication expansion is acceptable.

More from US FDA Performance Tracker

More from Regulatory Trackers